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Abstract 
The homeoprotein TLX1, which is essential
to spleen organogenesis and oncogenic when
aberrantly  expressed  in  immature  T  cells,
functions  as  a  bifunctional  transcriptional
regulator,  being  capable  of  activation  or
repression depending on cell type and/or pro-
moter context. However, the detailed mecha-
nisms by which it regulates the transcription
of target genes such as ALDH1A1 remains to
be  elucidated.  We  therefore  functionally
assessed  the  ability  of  TLX1  to  regulate
ALDH1A1 expression  in  two  hematopoietic
cell  lines,  PER-117  T-leukemic  cells  and
human erythroleukemic (HEL) cells, by use of
luciferase reporter and mobility shift assays.
We  showed  that  TLX1  physically  interacts
with the general transcription factor TFIIB via
its homeodomain, and identified two activi-
ties in respect to TLX1-mediated regulation of
the CCAAT box-containing ALDH1A1 promot-
er. The first involved CCAAT-dependent tran-
scriptional  repression  via  perturbation  of
GATA  factor-containing  protein  complexes
assembled  at  a  non-canonical  TATA  (GATA)
box. A structurally intact homeodomain was
essential  for  repression  by  TLX1  although
direct  DNA  binding  was  not  required.  The
second activity, which involved CCAAT-inde-
pendent  transcriptional  activation  did  not
require  an  intact  homeodomain,  indicating
that the activation and repression functions
of TLX1 are distinct. These findings confirm
ALDH1A1 gene regulation by TLX1 and sup-
port an indirect model for TLX1 function, in
which  protein-protein  interactions,  rather
than DNA binding at specific sites, are crucial
for its transcriptional activity.
Introduction 
TLX1 (HOX11), TLX2 and TLX3 belong to the
ancient NKL family of homeobox genes that
includes HEX, LBX1/2, MSX1/2, NKX3-2/BAPX1
and NKX2-5/CSX.
1 TLX1 encodes a transcrip-
tion factor that, although required during nor-
mal embryogenesis,
2,3 was actually discovered
as a consequence of its aberrant expression in
T-cell acute lymphoblastic leukemia (TALL).
4-7
Two distinct TLX1-expression categories have
been  identified  in  T-ALL.
8,9 High  level  TLX1
expression (13%) is typically associated with
10q24 chromosomal abnormalities and confers
a  favorable  prognosis  whereas  TLX1-low 
T-ALLs (22%) have an intact 10q24 locus and
expression  does  not  impact  prognosis.
9
Aberrant expression of related TLX3 is addi-
tionally found in another 22% of T-ALLs follow-
ing  5q35  chromosomal  rearrangements,
10
which  highlights  the  significant  role  of TLX
family members in T-cell oncogenesis. 
Confirmation that the gene product of TLX1
is an oncoprotein has come from mouse mod-
els, which have shown that enforced expres-
sion of TLX1 impairs cell differentiation and
leads to malignancy.
11-15 Current models for the
mechanism by which TLX1 promotes leukemia
are based on its ability to act indirectly, either
by enhancing chromosome instability
16,17 or by
regulating  gene  expression  through  specific
protein-protein interactions with key cellular
regulatory molecules such as the protein ser-
ine/threonine  phosphatases  PP1  and  PP2A,
and the transcriptional coactivator/acetyltrans-
ferase, CREB-binding protein (CBP).
18-20 Thus,
TLX1 may mediate its transforming function by
simultaneously  inhibiting  the  phosphatase
activity of PP1/PP2A to promote cell cycle pro-
gression via upregulation of pathways such as
those  downstream  of  E2F  and  MYC,
19 and
sequestering  CBP  at  heterochromatin  to
accomplish a differentiation block.
20
TLX1 has also long been suspected to act as
a sequence-specific transcription factor
21,22 that
preferentially  binds  to  the  core  sequence
TAA
T/GTG in vitro.
22,23 However, with the excep-
tion of its associations with heterochromatic
satellite  2  DNA
24 and  its  own  promoter,
25 no
direct target genes for TLX1 have been con-
vincingly identified. Individual genes suspect-
ed to be regulated by TLX1 have been described
in various settings, including spleen develop-
ment (Aldh1a1, Wt1),
26,27 erythroid differentia-
tion  (ALDH1A1,  c-Kit,  Vegfc),
15,28 and  T-cell
leukemia  (ALDH1A1,  FHL1,  NR4A3).
26,29,30
Nevertheless,  the  regulatory  role  that  TLX1
plays in such cases still remains to be deter-
mined. 
The  best  characterized  TLX1  target  gene,
ALDH1A1 (aldehyde  dehydrogenase  1A1)
belongs  to  a  subfamily  (class  1A)  of  ALDH
genes whose main biological role is the con-
version of the aldehyde form of vitamin A (reti-
nal)  to  its  biologically  active  form,  retinoic
acid.
31 ALDH1A1 apparently has normal roles in
embryonic  development,
32 and  in  the
renewal/differentiation of hematopoietic stem
cells (HSCs),
33 where it is known to be highly
expressed.
34 ALDH1A1 is further implicated in
regulating the polarity of HSC differentiation
by  favoring  the  development  of  a  myeloid
rather than a lymphoid cell fate.
30,35 In agree-
ment with this, ALDH1A1 expression can dis-
criminate between acute myeloid (AML) and
acute lymphoid leukemia,
36 and while we have
demonstrated  aberrant  ALDH1A1  expression
in T-ALL,
30 ALDH1A1 is reportedly down-regu-
lated in AML.
37 Thus, ALDH1A1, which is regu-
lated by TLX1 in its normal chromosomal con-
text
26,30 is  of  interest  due  to  its  associations
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with both normal development and leukemoge-
nesis. Here, we explored the molecular mecha-
nism(s) by which TLX1 regulates the ALDH1A1
gene and find that it occurs in a non-DNA bind-
ing  fashion  through  protein-protein  interac-
tions.  We  further  show  that  TLX1  interacts
directly with the general factor TFIIB via its
homeodomain, indicating a role for TLX1 in
gene regulation via the basal transcriptional
machinery. 
Design and Methods 
Cell culture and expression plasmids 
The PER-117 and ALL-SIL T-cell lines, and
erythroleukemic cell line HEL, were cultured
as previously described.
30 The coding regions
of human TLX1 and TFIIB were amplified by
RT-PCR  from  ALL-SIL  cDNA  generated  by
Thermoscript  RT  (Invitrogen,  Carlsbad,  CA,
USA)  using  PfuTurbo DNA  Polymerase
(Stratagene, La Jolla, CA, USA) and primers
containing  an  Nhe  I  restriction  site.  The
resulting products were cloned into the Nhe I
site of the pCINeo mammalian expression vec-
tor  (Promega,  Madison,  WI,  USA)  and
sequence verified. 
Luciferase reporter constructs 
The  human  ALDH1A1 proximal  promoter
region was amplified by high-fidelity PCR from
genomic DNA as previously described.
29 For the
construction of the -978/+42 construct, a 1020
bp  fragment  of  the  ALDH1A1 promoter  was
amplified  using  the  forward  primer  5’-
GCGAGCTCCACAATCAGAGCATCCAGAGTA-
3’and  reverse  primer  5’-GCGCTAGCCTCCTG-
GAACACAGGTGACTGGCT-3’  (introduced  Sac
I/Nhe I restriction sites in italics). To create
the -303/+42, -201/+42, -146/+42 and -91/+42
constructs,  various  lengths  of  the  ALDH1A1
promoter  were  amplified  using  the  same
reverse  primer  together  with  the  forward
primers  5’-GCGAGCTCAAAAAAATAATAACTG-
GCCTTAGTG-3’,  5’-GCGAGCTCCAGGTA-
CAAATTCGATGCTGGAGCACTGG-3’,  5’-
GCGAGCTCAAAGGCTTCCTGCCCTAGGTG-3’
and 5’-GCGAGCTCTGAGTTTGTTCATCCAATCG-
3’, respectively. The -50/+42 and +1/+42 con-
structs  were  generated  directly  by  oligonu-
cleotide  synthesis.  All  promoter  fragments
were directionally cloned into the Sac I/Nhe I
sites  of  the  luciferase  reporter  vector  pGL3-
Basic  (Promega,  Madison,  WI,  USA).  Insert
identities were confirmed by automated DNA
sequencing. The FHL1 -821 promoter construct
has been previously described.
38
Luciferase and β-galactosidase
reporter gene assays 
Plasmid DNAs (1 µg/µL), prepared using a
purification  kit  (Plasmid  Maxi,  QIAGEN,
Hilden, Germany), were transiently transfect-
ed as previously described.
39 In brief, PER-117
or HEL cells (1ￗ10
7) were co-transfected by
electroporation (300V, 960 µF) with 15 µg of
luciferase  reporter  plasmid  (or  as  negative
control,  pGL3-Basic)  and  5  µg  of  pSV-β-Gal
control  plasmid.  Cells  were  harvested  24  h
later followed by measurement of luciferase
and  β-galactosidase  activities  using  the
Tropix Dual-Light luminescent reporter gene
assay system (Applied Biosystems, Foster City,
CA, USA). Transcriptional activity was defined
as the ratio of luciferase activity (in relative
light units; RLU) from pGL3-Basic derivatives
relative to β-galactosidase activity from pSV-
β-Gal, which reflected the efficiency of trans-
fection. All experiments were repeated a total
of three times on different days. 
For  measuring  the  effect  of  TLX1  on
ALDH1A1 promoter  activity,  transfections
were similarly performed with the additional
inclusion  of  15  µg  of  expression  plasmid,
either  pEF-BOS/TLX1,  pEF-BOS/TLX1ʔH3  or
pEF-BOS as control.
40 In this case, transcrip-
tional activity was defined as the log (base 2)
transformation of the ratio of luciferase activ-
ity (in relative light units; RLU) from pGL3-
Basic  derivatives  relative  to  β-galactosidase
activity  from  pSV-β-Gal.  Statistical  analysis
was performed in SPLUS 2000 using a mixed
effects model with day of experiment as a ran-
dom  effect  and  luciferase  reporter  plasmid
and  expression  plasmid  as  fixed  effects.
Interactions  between  contrasts  comparing
pEF-BOS/TLX1  with  pEF-BOS,  and  contrasts
comparing  ALDH1A1 constructs  with  pGL3-
Basic,  were  examined.  This  revealed  the
extent to which the effect of adding TLX1 was
different for the various promoter constructs
compared to pGL3-Basic. 
Preparation of nuclear extracts 
Cells (1ￗ10
7) were washed twice with 10
mL of cold PBS, resuspended in 400 µl Buffer
A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM
EDTA, 0.1 mM EGTA) with protease inhibitors
(100  µg/mL  aprotinin,  5  µg/ml  leupeptin,  1
µg/ml pepstatin A, 0.5 mM PMSF) and incubat-
ed on ice for 30 min. 
NP-40 was added to a final concentration of
0.5% and the cells vortexed for 10 s. The nuclei
were pelleted by centrifugation at 6500 g for 1
min and resuspended in 100 µL Buffer C (20
mM  HEPES,  pH  7.9,  420  mM  NaCl,  1  mM
EDTA,  1  mM  EGTA,  20%  glycerol)  with  pro-
tease inhibitors. The nuclear suspension was
stirred vigorously on ice for 30 min. The sam-
ple was centrifuged at 13 000 g for 10 min, and
aliquots  of  the  nuclear  extract  were  frozen
immediately in liquid nitrogen and stored at
-80°C until required. The protein concentra-
tion of nuclear extracts was determined by the
Bradford  assay  (Bio-Rad  Laboratories,
Hercules, CA, USA). 
Electrophoretic mobility shift assay
(EMSA) 
Double-stranded  EMSA  probes  were  pre-
pared  from  the  following  oligonucleotides:
ALDH CAT (5’-AGTTTGTTCATCCAATCGTATCC-
GAG-3’),  ALDH  CATMut  (5’-AGTTTGTTCAT
gactgCGTATCCGAG-3’), ALDH GATAB (5’-GCC-
CGTGCAGATAAAAAAGGAACA-3’),  ALDH
GATABMut  (5’-GCCCGTGCActcagcAAAGGA
ACA-3’).  Probes  (20  pmol)  were  labeled  by
incubation (37°C for 30 min) with T4 polynu-
cleotide kinase (15 U, Gibco BRL) and 40 µCi
[γ
32P]-ATP (3000 Ci/mmol) in a volume of 20
µL.  The  radiolabeled  probes  were  purified
using  Microspin  G-50  columns  (Amersham
Biosciences)  and  made  double-stranded  by
annealing with an equimolar amount of com-
plementary oligonucleotide in 1 x annealing
buffer (10 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1
mM EDTA). Probes were incubated in 1 x bind-
ing buffer (20 mM HEPES, pH 7.6, 50 mM KCl,
1 mM EDTA, 1 mM DTT, 5% glycerol) with 0.5
µg  poly(dI-dC)  (ICN,  Costa  Mesa,  CA,  USA)
and 6 µg of nuclear extract in a final volume of
15 µL. The samples were incubated at 4°C for
30 min and then analyzed by electrophoresis
on 4% native polyacrylamide gels in 0.5 x TBE
at 10 V/cm. For competition experiments, an
excess of unlabeled competitor oligonucleotide
was  added  to  reaction  mixtures.  Additional
competitor oligonucleotides used were those
containing  TLX1  (5’-TTCCATTCGATAATTC-
CATTCGA-3’)  or  GATA  (5’-GAAACCTGT-
GATAAGTGTATGCAG-3’)  binding  sites.
Bandshifts were performed in the presence of
anti-TLX1 by adding 2 uL of polyclonal rabbit
antiserum raised against the C-terminus (sc-
880,  Santa  Cruz  Biotechnology,  Santa  Cruz,
CA). Normal rabbit serum was used for the no
antibody  control.  Following  electrophoresis,
the  gels  were  transferred  to  3MM  paper
(Whatman, Maidstone, UK), dried and autora-
diographed at -80°C. 
Western blotting and immunopre-
cipitation of TLX1 complexes 
Western blotting was performed with 50 ug
of nuclear extract electrophoresed through a
12% SDS-PAGE gel and transferred to a Hybond
ECL membrane (AP Biotech, Little Chalfont,
UK). The membrane was blocked overnight in
TBS-Tween buffer (1 mM Tris, 7.5 mM NaCl,
0.05%  v/v  Tween-20)  containing  3.5%  (w/v)
gelatin and incubated with 1:1200 diluted rab-
bit anti-TLX1 antiserum (sc-880, Santa Cruz
Biotechnology) (1 h, RT). The membrane was
incubated  with  HRP-conjugated  secondary
antibody  (1  h,  RT)  prior  to  visualization  of
bands  by  enhanced  chemiluminescence  (AP
Biotech).  For  immunoprecipitation,  nuclear
extract  from  ALL-SIL  cells  (5ￗ10
6)  was  pre-
cleared  with  the  addition  of  protein  A/G
agarose  (Santa  Cruz  Biotechnology)  for  15
min at 4°C. Pre-cleared extracts were incubat-
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ed with 5 µg of affinity-purified rabbit anti-
TLX1 polyclonal antibody (sc-880; Santa Cruz
Biotechnology), or no antibody (as control), for
4  h  at  4°C  with  constant  gentle  rocking.
Immune complexes were bound to protein A/G
agarose beads, centrifuged and washed with
1.2 mL of cold IP wash buffer (100 mM Tris-HCl
pH 7.4, 1% NP40 and 1% deoxycholic acid) con-
taining 500 mM LiCl (once) and 1.2 mL of IP
wash buffer (four times). 
MALDI-TOF mass spectrometric
analyses 
Immunoprecipitated proteins were resolved
by  SDS-PAGE  and  visualized  by  silver  stain-
ing.
41 Bands  were  excised  directly  from  gels
into  96-well  microtiter  plates  (Titertek,
Huntsville,  AL,  USA),  destained,
42 and  in-gel
trypsin  digestions  performed  according  to
Shevchenko  et  al.
41 Peptides  were  extracted
with  10  mg/mL  α-cyano-4-hydroxycinnamic
acid in 50% acetonitrile containing 0.1% triflu-
oroacetic acid, and aliquots of 0.5 uL applied
directly onto a target plate and allowed to air
dry. Tryptic peptide masses were then obtained
using  a  Voyager-DE  STR  MALDI-TOF  mass
spectrometer (Applied Biosystems, Foster City,
CA, USA). Known trypsin autocleavage peptide
masses (842.51, 1045.56 and 2211.1 Da) were
used for internal calibration of each spectrum.
The peptide masses were used to search the
Swiss-Prot  and  NCBI  nr  protein  databases
using the MS-FIT database tool. A protein was
considered to be identified if a minimum of
five measured peptide masses matched calcu-
lated tryptic peptide masses and if the peptides
identified by these matches provided at least
20% sequence coverage of the identified pro-
tein. 
GST-pulldown assay 
TLX1 and TFIIB cDNAs in pCIneo were tran-
scribed in vitro with T7 RNA polymerase. The
products were labeled with [
35S]-methionine
(Amersham Biosciences) using the TNT cou-
pled transcription-translation system (Prome-
ga). GST-TLX1 fusion proteins were expressed
from pGEX-6P-1 as described previously.
43 The
GST-pulldown assay was performed by incubat-
ing 15 µg of GST, GST-TLX1 or GST-TLX1ʔH3
immobilized on glutathione sepharose beads
(20 µL) with 5 µl of proteins translated in vitro
and labeled with [35S]-methionine in 500 µL
of binding buffer (50 mM Tris-HCl, pH 7.5, 150
mM NaCl, 0.5 mM EDTA, 0.5% NP-40, 1 mM
DTT, 0.5 mM PMSF, 0.05% BSA) for 18-20 h at
4°C with continuous rotation. Bound proteins
were washed three times with 500 µL of cold
binding  buffer  and  eluted  in  SDS  sample
buffer. The eluted proteins were resolved on
12% SDS-PAGE gels and visualized by autora-
diography. 
Results 
Functional analysis of the human
ALDH1A1 promoter 
Ectopic expression of TLX1 was previously
shown  to  modulate  endogenous  ALDH1A1
expression.
26,30,38 To  pursue  the  molecular
mechanism(s)  underlying  this  regulatory
effect,  we  cloned  1020  bp  of  the  human
ALDH1A1 5’-flanking  region  into  the  pGL3-
Basic luciferase reporter vector. This sequence
comprised nucleotides -978 to +42 relative to
the transcriptional start site (Figure 1). Among
the  conserved  promoter  elements  identified
were a TATA-like sequence (GATA box) at -33
and a single CCAAT box at -74, which has pre-
viously been shown to be functionally impor-
tant  for  ALDH1A1 expression.
44 Transient
transfection of a series of deletion constructs
(-978/+42, -303/+42, -201/+42, -146/+42, -91/
+42, -50/+42 and +1/+42; Figure 1) into PER-
117  and  HEL  cells  (which  both  lack  TLX1
expression) showed that the ALDH1A1promot-
er was functional in both cell lines and that the
sequences between -50 and -91 and between -
50 and -146 were required for maximal promot-
er activity in PER-117 and HEL cells, respec-
tively  (Figure  2A).  Consistent  with  previous
results in Hep3B liver cells,
44 deletion of the
CCAAT box at -74 caused a dramatic reduction
in promoter activity, suggesting that it is a key
element for ALDH1A1 expression in multiple
cell types. 
Regulation of the ALDH1A1 pro-
moter by TLX1 
To determine the effect of TLX1 on the tran-
scriptional activity of the ALDH1A1 promoter,
transactivation  assays  were  carried  out  in
PER-117 and HEL cells co-transfected with an
expression plasmid containing TLX1 or empty
vector (pEF-BOS) as a negative control. The
results were expressed as a ratio of the nor-
malized transcriptional activity of each of the
two  promoter  constructs  with  and  without
TLX1 (Figure 2B). Western blot analysis con-
firmed that TLX1 protein was expressed in the
transfected cells (Figure 2C). Consistent with
our previous findings,
15,29,38 the effect of TLX1
Article
Figure 1. Nucleotide sequence alignment of the human and mouse ALDH1A1 promoters.
Conserved nucleotides are marked with an asterisk. Numbers at right indicate nucleotide
positions of the human sequence relative to the transcriptional start site (bent arrow).
Potential regulatory elements, including a conserved TLX1 site at -257, are boxed and
labeled. Solid triangles with numbers demarcate the 5’ ends of the promoter deletion con-
structs used in the luciferase reporter assays. The two regions used for gel shift analysis
are underlined at -85 to -60 and -42 to -19. BRE, TFIIB recognition element. [Hematology Reviews 2009; 1:e13] [page 73]
on ALDH1A1 was reversed in the transcription-
al  assay  as  compared  to  regulation  of  the
endogenous  gene.  In  PER-117  cells,  TLX1
repressed ALDH1A1 promoter activity (Figure
2B), and this required the sequence between 
-50 and -91, which contains the CCAAT box.
Deletion  of  the  CCAAT  box  (-91ʔCAT)  com-
pletely  abolished  TLX1-mediated  repression
(Figure 2B), suggesting that downregulation
may possibly occur via this site. Interestingly,
the shortest constructs (-50/+42 and +1/+42)
were mildly stimulated by TLX1 in both PER-
117 and HEL cells, (Figure 2B) indicating the
presence of a separate, positive-acting TLX1-
response  sequence  localized  to  the  region
between +1 and +42. No effect by TLX1 was
observed on the region between -201 and -303,
which contains a conserved TLX1 in vitro bind-
ing  site  at  -257  (Figure  1),  suggesting  that
TLX1 binds to a distinct recognition sequence
in the ALDH1A1 promoter in vivo, or alterna-
tively, that it acts via a non-DNA binding mech-
anism. In either case, these data indicate that
TLX1 operates via at least two mechanisms in
respect to the ALDH1A1 promoter; a general
transactivating activity via an element located
between +1 and +42 and a strong, cell line-
specific  repressive  activity  via  an  element
located between -91 and -50. 
The homeodomain is required for
TLX1-mediated repression 
To  assess  whether  the  homeodomain  of
TLX1 is required for the transcriptional activi-
ties of TLX1, a mutant TLX1 expression vector
(TLX1ʔH3)  was  employed,  which  lacks  the
DNA recognition helix (helix 3) of the home-
odomain. Whereas, TLX1 repressed the activity
of the basal ALDH1A1 promoter (-91/+42) 4-
fold in PER-117 cells, TLX1ʔH3 not only lacked
the ability to negatively regulate ALDH1A1, but
switched to become an activator, stimulating
transcription by approximately 5-fold (Figure
3). A similar result was obtained when the pro-
moter of another target gene, FHL1,
38 was used
(Figure 3). By contrast, the positive regulation
of the -91/+42 construct observed in HEL cells
was comparable when either TLX1 or TLX1ʔH3
was used (5.5-and 8-fold induction, respective-
ly).  Thus,  the  homeodomain  is  crucial  for
TLX1-mediated repression but is not required
for TLX1-mediated activation, indicating that
these two activities are distinct. 
TLX1 does not affect formation of
transcriptional complexes at the -74
CCAAT site 
We  opted  to  focus  on  the  mechanism  by
which  TLX1  mediates  CCAAT-dependent
repression. Mobility shift assays were there-
fore  performed  to  identify  whether  TLX1
directly binds to the CCAAT box or interferes
with the binding of other factors at this site.
Nuclear extracts derived from PER-117 or HEL
cells,  either  expressing  empty  pEF-BOS  (as
control)  or  pEF-BOS/TLX1,  were  incubated
with a radiolabeled probe (ALDH CAT) span-
ning the CCAAT motif (-85 to -60; Figure 1). As
shown  in  Figure  4A,  incubation  of  nuclear
extract from PER-117 or HEL cells with ALDH
CAT resulted in the appearance of at least two
specific DNA-protein complexes, together with
a  third  non-specific  complex  (C2).  The
strongest, complex C1, appeared to be common
to the two cell types, while additional complex-
es P and H were unique to PER-117 and HEL
cells,  respectively.  These  complexes  were
inhibited  by  the  addition  of  a  35-fold  molar
excess  of  unlabeled  self-competitor  (ALDH
CAT)  but  not  by  a  35-fold  molar  excess  of
CCAAT  mutant  competitor  (ALDH  CATMut;
CCAAT to GACTG). Contrary to expectation, in
both PER-117 and HEL cells the mobility shift
pattern  was  identical  regardless  of  TLX1
Article
Figure  2.  Activity  of  the  human
ALDH1A1 promoter and its differential
regulation by TLX1. (A) ALDH1A1 pro-
moter activity in the hematopoietic cell
lines PER-117 and HEL. Luciferase activ-
ity expressed as fold-change over the pro-
moter-less pGL3-Basic vector after nor-
malizing  the  luciferase  signals  to  a  β-
galactosidase  transfection  control.  The
indicated  ALDH1A1 promoter  deletion
constructs  were  transiently  transfected
into PER-117 cells (black bars) and HEL
cells (gray bars). Deletion of the CCAAT
box (-91ʔCAT construct) abrogates pro-
moter activity. The values represent the
average  of  duplicate  data  points  from
three independent experiments. (B) The
ALDH1A1 promoter is differentially reg-
ulated  by TLX1  in  PER-117  and  HEL
cells. The indicated ALDH1A1 luciferase
reporter constructs were co-electroporat-
ed with a TLX1 expression plasmid and
β-galactosidase  expression  plasmid  into
the cell lines PER-117 (black bars) and
HEL  cells  (gray  bars).  Transactivation/
repression  is  shown  as  the  fold-change
(on  a  log2  scale)  compared  to  back-
ground  levels  obtained  when  an  empty
expression vector (no TLX1) was co-elec-
troporated. Asterisks denote fold changes
that  were  statistically  different  to  zero
(p<0.05).  The  -91ʔCAT  construct  har-
bors a deletion of the CCAAT box. (C)
Western  blot  confirming  TLX1  protein
expression in the transiently transfected
PER-117 and HEL cells. U, untransfect-
ed  controls;  T,  TLX1  transfected.  The
faint  band  observed  in  the  controls  is
non-specific. 
Figure 3. TLX1 requires an intact home-
odomain  for  transcriptional  repression
but  not  activation  in  vitro.  Luciferase
activity  of  the  ALDH1A1 -91/+42  and
FHL1 -821/+181  promoter  constructs
cotransfected into the indicated cell lines
with either an empty expression vector as
negative  control  (striped  bars),  TLX1
(black bars) or TLX1ʔH3, a mutant lack-
ing  helix  3  of  the  homeodomain  (gray
bars). The values represent the average of
duplicate  data  points  from  three  inde-
pendent experiments. 
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expression status (or addition of TLX1 anti-
body; data not shown), suggesting that TLX1
does not affect the formation of DNA-protein
complexes at the CCAAT box. 
TLX1 alters DNA-protein complex
formation at the -33 GATA box 
TLX1  may  directly  or  indirectly  inhibit
CCAAT-dependent transcription via the basal
apparatus.  The  ALDH1A1 promoter  lacks  a
canonical TATA box but does possess a related
GATA box (GATAAA) utilized by a number of
genes whose transcriptional initiation involves
interplay between TFIID and GATA factors.
45-48
EMSAs  were  thus  performed  to  identify
whether TLX1 directly binds to the GATA box or
interferes with the binding of other factors at
this site. Nuclear extracts derived from PER-
117 or HEL cells, either expressing empty pEF-
BOS (as control) or pEF-BOS/TLX1, were incu-
bated with a radiolabeled probe (ALDH GATAB)
spanning the GATA box (-42 to -19; Figure 1).
As shown in Figure 4B, incubation of nuclear
extract  from  PER-117  cells  lacking  TLX1
expression with ALDH GATAB resulted in the
appearance of four specific DNA-protein com-
plexes, C1, C2, P1 and P2. HEL nuclear extracts
only produced three specific complexes (C1,
C2  and  H),  the  strongest  of  which  (C2)
appeared  to  migrate  similarly  in  both  cell
types. These complexes were inhibited by the
addition of a 35-fold molar excess of unlabeled
self-competitor (ALDH GATAB) but not by a 35-
fold molar excess of GATA box mutant competi-
tor  (ALDH  GATABMut;  GATAAA  to  CTCAGC).
Strikingly,  in  PER-117  but  not  HEL  cells,
expression of TLX1 resulted in a significant
alteration in complex formation. Of the four
specific PER-117 complexes, the formation of
two (C1 and P1) was completely inhibited by
TLX1, while the intensity of the remaining two
(C2 and P2) was enhanced. Thus, TLX1-medi-
ated regulation of ALDH1A1 in T cells, but not
erythroid cells, is associated with an alteration
of transcription factor binding at the GATA box. 
Complex formation at the GATA box in both
PER-117 and HEL cells was also strongly inhib-
ited when a 35-fold molar excess of an unla-
beled consensus GATA oligonucleotide (GATA;
containing  WGATAR  with  different  flanking
sequences to ALDH GATAB) was used (Figure
5A). This indicated that GATA factors are pres-
ent  in  all  complexes  formed  in  this  assay.
However, TLX1 does not appear to bind DNA at
this site, since a 35-fold molar excess of an
unlabeled  consensus  satellite  2  oligonu-
cleotide  (TLX1),  capable  of  being  bound  by
TLX1,
24 could not compete for complex forma-
tion (Figure 5A). In agreement with this con-
clusion, no supershift or inhibition of complex
formation was observed following addition of
TLX1 antibody (Figure 5B). Notably, however,
PER-117  complex  C1,  which  is  abolished  by
TLX1, re-formed in the presence of TLX1 anti-
body, indicating that TLX1 directly contributes
to the disruption of this low mobility complex. 
TLX1 interacts with TFIIB 
To help understand the transcriptional regu-
latory function of TLX1, we searched for bind-
ing  partners  using  an  immunoprecipitation
strategy  in  leukemic  T  cells  (ALL-SIL)  that
Article
Figure 4. Effect of TLX1 on ALDH1A1 promoter DNA-binding complexes. (A) TLX1 does not affect DNA-protein complex formation
at the -74 CCAAT box. EMSA using a 
32P-labeled double-stranded oligonucleotide containing the CCAAT site at -74 of the human
ALDH1A1 promoter (ALDH CAT). The assay was performed with nuclear extracts prepared from PER-117 (left lanes) or HEL cells
(right lanes) with and without overexpression of TLX1. The migration of the free probe is indicated along with the positions of specif-
ic DNA-protein complexes (C1 and P in PER¬117 cells; C1 and H in HEL cells). Overbars denote the addition of a 35-fold molar
excess of unlabeled double-stranded self (ALDH CAT) or mutant (ALDH CATMut) probe as competitor. (B) TLX1 alters DNA-pro-
tein complex formation at the -33 GATA box. EMSA performed as above using a labeled oligonucleotide containing the GATAAA site
at -33 of the human ALDH1A1 promoter (ALDH GATAB). The migration of the free probe is indicated along with the positions of
specific DNA-protein complexes (C1, C2, P1 and P2 in PER-117 cells; C1, C2 and H in HEL cells). Overbars denote the addition of
a 35-fold molar excess of unlabeled double-stranded self (ALDH GATAB) or mutant (ALDH GATABMut) probe as competitor.
Asterisks denote complexes altered by TLX1. 
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aberrantly express TLX1 as a consequence of a
10q24  chromosomal  translocation.  A  TLX1
antibody  was  employed  to  isolate  naturally
occurring  nuclear  protein  complexes,  which
were  separated  by  SDS-PAGE  and  silver
stained (Figure 6A). Excised gel slices repre-
senting  discrete  molecular  mass  intervals
were  digested  with  trypsin  and  analyzed  by
MALDI-TOF  mass  spectrometry  in  order  to
determine the identity of the protein bands.
Table 1 summarizes the eight proteins detect-
ed.  Among  these  were  the  centromeric  pro-
teins CENP-E and CENP-F, an intriguing find-
ing given that TLX1 has previously been local-
ized  to  centromeric  regions.
24 Of  particular
interest was the detection of the general tran-
scription factor TFIIB, which was identified by
the presence of 15 peptides with sequence cov-
erage of 49% (Table 1). To confirm that TLX1
could physically interact with TFIIB in a specif-
ic manner, we performed a GST pulldown assay
(Figure  6B).  Glutathione-Sepharose  beads
containing  GST-TLX1,  GST-TLX1ʔH3,  or  GST
alone were incubated with in vitro translated
35S-labeled  TFIIB  or  TLX1  protein.  The  latter
was included as a positive control since TLX1
has previously been shown to homodimerize.
24
Following  extensive  washing,  retention  of
TFIIB  was  observed  with  GST-TLX1  but  not
with control GST beads (Figure 6B), demon-
strating that TLX1 has the capacity to interact
with  TFIIB.  Interestingly,  retention  of  TFIIB,
but not TLX1 control, was greatly diminished
when GST-TLX1ʔH3 beads were used, indicat-
ing that helix 3 of the TLX1 homeodomain con-
tributes strongly to the TFIIB interaction. 
Discussion 
TLX1 has previously been characterized as a
DNA-binding factor that preferentially associ-
ates with the core sequence TAA
T/GTG in vitro
22,23 and the similar sequence T
A/GATTC present
in  satellite  2  DNA.
24 In  addition,  TLX1  can
switch, in a cell type- and promoter context-
dependent manner, between roles as activator
and repressor,
26,30,38 however the mechanism(s)
responsible for these divergent roles is poorly
understood. In this study, we further investi-
gated  the  function  of  TLX1  by  analyzing  its
ability to transcriptionally regulate ALDH1A1, a
gene  previously  identified  as  being  TLX1-
dependent in developing mouse spleen as well
as in several cell lines (PER-117, HEL, NIH-
3T3),
26,30,49 and which contains a predicted TLX1
binding site, conserved between human and
mouse, at -257 upstream of the transcriptional
start site. In the first instance, our data con-
firmed ALDH1A1as a regulatory target of TLX1,
with the polarity of effect observed in terms of
activation/repression being heavily dependent
upon cell type. In PER-117 T cells, transient
luciferase  reporter  assays  with  nested  dele-
tions of the ALDH1A1 promoter revealed that
TLX1-mediated  repression  occurred  in  a
CCAAT  box-dependent  manner  involving  an
element located between -91 and -50. By con-
trast,  TLX1  stimulated  transcription  in  a
CCAAT-independent manner from a proximal
location (-91/+42) in human erythroleukemic
Article
Figure 5. Perturbation of GATA-containing complexes by TLX1. (A) GATA factor(s) but not TLX1 binds to the ALDH1A1 promoter
GATA box. EMSA using a 32P-labeled double-stranded oligonucleotide containing the GATAAA site at -33 of the human ALDH1A1
promoter (ALDH GATAB). The assay was performed with nuclear extracts prepared from PER-117 (left panel) or HEL cells (right
panel) with and without overexpression of TLX1. The migration of the free probe is indicated along with the positions of specific DNA-
protein complexes (C1, C2, P1 and P2 in PER-117 cells; C1, C2 and H in HEL cells). Overbars denote the addition of a 35-fold molar
excess of unlabeled double-stranded self (ALDH GATAB), satellite 2 DNA (TLX1) or GATA consensus (GATA) probe as competitor.
Asterisks denote complexes altered by TLX1. (B) TLX1 directly disrupts the low mobility ALDH1A1 promoter GATA box complex C1.
EMSA performed as above using the -33 GATAAA site oligonucleotide (ALDH GATAB) in the absence (-) or presence (+) of TLX1 anti-
body. The migration of the free probe is indicated along with the positions of specific DNA-protein complexes (C1, C2, P1 and P2 in
PER-117 cells; C1, C2 and H in HEL cells). Complex C1 reappears in PER-117 cells expressing TLX1 in the presence of anti-TLX1
antibody (asterisk). 
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(HEL) cells. Transactivation, which was also
observed in the T-cell background when a min-
imal promoter sequence was used (-50/+42),
was abolished in HEL cells with the addition of
extra  DNA  sequence  (-146/-92)  suggesting
that a specific factor bound to this region is
capable of abrogating the stimulatory potential
of TLX1. Thus, TLX1 possessed two activities in
respect  to  the  ALDH1A1 promoter,  namely
CCAAT-dependent repression, which was cell
type-specific and cryptic CCAAT¬independent
activation, which was unmasked by deleting
upstream  regulatory  sequences.  Neither  of
these activities involved the TLX1 recognition
site  at  -257,  which  initially  suggested  that
TLX1 either bound a distinct sequence in vivo,
as is the case with the regulation of its own
promoter,
25 or that it acted via a non-DNA bind-
ing mechanism. 
Remarkably, the effect of TLX1 on ALDH1A1
promoter  activity  in  the  transient  reporter
assays was inversely related to its previously
observed effect on endogenous ALDH1A1 lev-
els in PER-117 and HEL cells.
30 This phenome-
non has been observed previously in respect to
other putative gene targets of TLX1, namely
NR4A3, KIT and FHL1.
15,29,38 Although puzzling,
the finding that a homeoprotein can act as a
repressor or activator of transcription depend-
ing on promoter context is a common one. In
many cases the activity that predominates has
been  found  to  be  highly  dependent  on  the
nature  of  the  cis-regulatory  DNA  sequence
since this can, in turn, affect the interaction of
homeoproteins  with  co-regulatory  molecules
such as TALE (three amino acid loop exten-
sion) homeoproteins, CBP (CREB-binding pro-
tein) or Groucho.
50-54
CCAAT-dependent  repression  by  TLX1  was
found  to  require  the  DNA  recognition  helix
(helix  3)  of  the  homeodomain.  Intriguingly,
the  TLX1ʔH3  mutant  lacking  this  helix  was
not  only  incapable  of  repressing  ALDH1A1
transcription in PER-117 cells but switched to
become an activator of transcription. This indi-
cated that the repression/activation activities
of TLX1 are separable with a structurally intact
homeodomain  being  absolutely  required  for
transcriptional repression, but not activation.
Given these findings, a reasonable assumption
was that TLX1 would repress ALDH1A1 tran-
scription by directly binding promoter DNA at
or near the CCAAT box. This crucial element is
likely generally required for ALDH1A1 expres-
sion, since it was also identified as the major
positive element in the Hep3B cell line and in
Hepa-1  mouse  hepatoma  cells  where  it  was
bound by NF-Y and CCAAT/enhancer binding
protein β (C/EBPβ), respectively.
44,55 Moreover,
the CCAAT box is capable of being bound by
the  CCAAT  binding  transcription  factor
(CTF1/NFIC)  with  which  TLX1  is  known  to
interact  in  a  functional  manner.
56 However,
EMSA assays using PER-117 (or HEL) nuclear
extracts  revealed  that  TLX1  did  not  directly
bind the CCAAT box, nor did it affect protein
Article
Table 1. Proteins identified by immunoprecipitation and peptide mass fingerprinting.
Identified protein Matched Mass UniProtKB/Swiss-Prot
peptide cover (kDa) accession number
(%)
General transcription factor IIB (TFIIB) 49 34.83 Q00403
Centromere protein F (CENPF) 39 367.76 P49454
Centromere protein E (CENPE) 35 316.42 Q02224
RAD50 homolog (RAD50) 31 153.89 Q92878
Retinoblastoma binding protein 9 (RBBP9) 28 21.00 O75884
NK homeobox 6-1 (NKX6-1) 28 37.85 P78426
Lymphoblastic leukemia 1 (LYL1) 23 28.63 P12980
Zinc finger protein 20 (ZNF20) 20 61.57 P17024
Figure 6. TLX1 interacts with TFIIB.
(A) Isolation of TLX1-associated pro-
teins. Nuclear extracts from ALL-SIL
leukemic T cells were immunoprecip-
itated  using TLX1-specific  antibody
(Ab), or no antibody (No Ab) as neg-
ative control. Coprecipitated proteins
were resolved by SDS-PAGE and sil-
ver stained. (B) GST pulldown assay.
GST, GST-TLX1 and GST-TLX1ʔH3
immobilized  on  glutathione-
Sepharose beads were incubated with
in vitro-translated, 
35S-labeled TLX1
as  positive  control,  and  TFIIB.
Bound proteins were washed, eluted,
resolved  by  12%  SDS-PAGE  and
detected by autoradiography: 50% of
the labeled input proteins TLX1 and
TFIIB are shown on the left. 
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complex formation at this site. We therefore
hypothesized that TLX1 may abrogate CCAAT-
dependent transcription of ALDH1A1 by acting
through  the  basal  transcriptional  apparatus.
Supporting  this  notion,  a  previous  study
demonstrated that TLX1 is capable of repress-
ing  transcription  via  the  RNA  polymerase  II
holoenzyme  in  a  manner  that  is  DNA-inde-
pendent,  yet  requires  helix  3  of  the  home-
odomain.
49 Indeed, we found that TLX1 altered
the formation of GATA-containing protein com-
plexes at the non-canonical TATA (GATA) box
located at -33 on the ALDH1A1 promoter and
that this occurred specifically in PER-117 cells
where repression by TLX1 was observed. The
GATA box is a dual regulatory site capable of
binding both GATA factors and members of the
basal transcriptional machinery, which is over-
represented  among  erythroid-specific  gene
promoters. Studies to date have indicated that
the GATA box is a specialized/weakened TATA
box
57 whose  activity  depends  on  interplay
between binding of GATA factors and general
transcription factors such as TFIID.
45-48 Based
on our data, we therefore postulate that TLX1
can operate as a transcriptional repressor by
altering the balance between specific factors
binding at the GATA box without actually bind-
ing  DNA  itself.  This,  at  least  in  part,  may
involve direct protein contacts by TLX1 since
inclusion  of  anti-TLX1  antibody  into  EMSA
binding  reactions  reduced  TLX1-associated
inhibition of one of the GATA box complexes
identified. Intriguingly, the related HEX pro-
tein has been reported to interact with GATA2
to inhibit its binding to the flk-1/KDR gene,
58
suggesting that direct antagonism of GATA fac-
tors may be a feature of NKL homeoprotein
function more generally. 
We  further  showed  that  TLX1  specifically
interacts with TFIIB, a member of the general
transcriptional  machinery.  TFIIB,  which  can
bind  promoter  DNA  in  a  sequence-specific
manner at a TFIIB recognition element (BRE),
plays a central role in pre-initiation complex
(PIC)  assembly,  providing  a  bridge  between
promoter-bound TFIID and RNA polymerase II.
This points to a mechanism to account for how
TLX1 can inhibit basal transcription in a non-
DNA binding manner, both in this study and
that of Owens et al.
49 Specifically, TLX1 may
directly affect repression of the ALDH1A1 pro-
moter, which contains a BRE adjacent to the
GATA box, by inhibiting the rate/extent of PIC
formation via contacts with TFIIB. Notably, the
TLX1-TFIIB  interaction  was  reduced  in  the
absence  of  homeodomain  helix  3.  Thus  our
results  provide  one  potential  mechanism  to
explain the switch in activity from repression
to  activation  observed  with  the  TLX1ʔH3
mutant. 
Significantly, it has been recently reported
that  TLX1,  like  many  other  homeoproteins,
52
can form a mutually inhibitory complex with
the co-activator/histone acetyltransferase mol-
ecule CBP.
20 This interaction leads to seques-
tration  of  CBP  at  repressive  chromatin
domains, which is consistent with our previ-
ous  finding  that  TLX1  can  localize  to  hete-
rochromatin via binding at satellite 2 DNA.
24
The TLX1-CBP interaction was also shown to
require  helix  3  of  the  TLX1  homeodomain,
thereby  suggesting  an  alternative,  although
not mutually exclusive, explanation for TLX1-
mediated  repression  and  its  reversal  in  the
TLX1ʔH3 mutant. Riz et al.
20 further showed a
correlation between the presence of TLX1 and
a lack of CBP-associated acetylation of GATA1.
As is the case for GATA2 and GATA3,
59,60 the
DNA  binding  and  transcriptional  activity  of
GATA1 is heavily dependent on its acetylation
status.
61 Taken together, we suggest a model in
which  interactions  between  TLX1  and  both
TFIIB  and  CBP  lead  to  the  transcriptional
repression observed in our transient luciferase
assays.  Whereas  contacts  with  TFIIB  may
inhibit the formation of a functional PIC, bind-
ing to CBP may prevent it functioning as a co-
activator and acting to acetylate GATA factors.
This  would  explain  the  substantially  altered
formation  of  GATA-containing  protein  com-
plexes  observed  at  the  ALDH1A1 promoter
GATA box, despite the lack of DNA binding by
TLX1. It is conceivable that a general ability of
TLX1  to  indirectly  regulate  target  genes  by
altering GATA factor activity, whether via CBP
or an alternative mechanism, may be conse-
quential for its role as an oncoprotein. This is
particularly in view of evidence linking both a
blockage in T-cell development and leukemo-
genesis  to  incapacitated  GATA  function.
62,63
Interestingly,  a  non-DNA  binding  mode  of
action for TLX1 that involves activity regula-
tion of other transcription factors is reminis-
cent of another important T-ALL oncoprotein,
SCL/TAL1, which induces leukemia by recruit-
ing  the  co-repressor/histone  deacetylase
mSin3A to inhibit the transcriptional activity
of E47/HEB.
64
There is little evidence to date showing that
TLX1  can  bind  directly  to  natural  DNA
sequences to regulate target gene expression.
Instead, TLX1 has been shown to operate indi-
rectly by interacting with other proteins, most
notably the phosphatases PP1 and PP2A to reg-
ulate gene cascades in various pathways such
as RB/E2F and p107/MYC.
18,19 Consistent with
this paradigm, our data confirm that TLX1 is
capable of regulating ALDH1A1 expression in a
non-DNA  binding  manner  by  affecting  tran-
scriptional  complexes  at  the  proximal
ALDH1A1 promoter, although clearly, addition-
al cis-regulatory elements (that may influence
TLX1  protein  interactions)  are  required  to
recapitulate the effect of TLX1 on endogenous
ALDH1A1 gene  expression.  We  showed  that
TLX1,  like  other  homeodomain  transcription
factors including tinman/Nkx2-5, abdominal-A,
Nkx6.1 and Vnd/Nkx2-2
51,53,54,65 is capable of act-
ing as a bi-functional transcriptional regulator,
whose  activation  and  repression  activities
operate in a cell-type specific manner and via
two  distinct  mechanisms.  The  first  involves
the  ability  of  TLX1  to  repress  transcription,
possibly  by  perturbing  interactions  between
CCAAT box-binding transcriptional activators
and proteins (GATA factors/basal transcription-
al machinery) assembled at a non-canonical
TATA (GATA) box. This activity does not appear
to  involve  direct  DNA  binding,  although  a
structurally intact homeodomain is required,
presumably in order for TLX1 to interact with
TFIIB and/or CBP. Chromatin immunoprecipi-
tation assays to identify the specific transcrip-
tion factor(s) bound at this composite CCAAT-
box/TLX1 responsive element and at the GATA
box  before  and  after  TLX1  expression  are
required to substantiate this hypothesis. The
second activity involves the ability of TLX1 to
stimulate transcription through as yet uniden-
tified  regulatory  elements  in  the  proximal
ALDH1A1 promoter and does not require an
intact  homeodomain.  Our  understanding  of
the role of TLX1 in normal development and in
T-cell leukemogenesis is crucially dependent
on  deciphering  the  mechanisms  by  which
TLX1 is capable of regulating gene expression.
Future work to characterize TLX1 target genes
and  to  fully  define  the  protein  participants
involved  in  TLX1-mediated  gene  regulation
will  represent  important  steps  towards  this
goal. 
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